Today’s Stock On Watch: Celator Pharmaceuticals Inc Sentiment Worsening on Low Stock Potential

November 21, 2016 - By Dolores Ford   ·   0 Comments

Today's Stock On Watch: Celator Pharmaceuticals Inc Sentiment Worsening on Low Stock Potential

Sentiment for Celator Pharmaceuticals Inc (NASDAQ:CPXX)

Celator Pharmaceuticals Inc (NASDAQ:CPXX) institutional sentiment decreased to 0 in 2016 Q2. Its down -2.90, from 2.9 in 2016Q1. The ratio dived, as 90 investment managers increased or started new holdings, while 31 sold and reduced their holdings in Celator Pharmaceuticals Inc. The investment managers in our partner’s database now possess: 35.45 million shares, down from 36.97 million shares in 2016Q1. Also, the number of investment managers holding Celator Pharmaceuticals Inc in their top 10 holdings increased from 3 to 8 for an increase of 5. Sold All: 21 Reduced: 10 Increased: 20 New Position: 70.

Celator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The company has a market cap of $1.28 billion. The Firm is engaged in developing products to improve patient outcomes in cancer. It currently has negative earnings. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

The stock closed at $30.24 during the last session. It is down 6.00% since October 22, 2016 and is uptrending. It has outperformed by 2.14% the S&P500.

Caxton Corp holds 76% of its portfolio in Celator Pharmaceuticals Inc for 2.23 million shares. Venbio Select Advisor Llc owns 1.12 million shares or 7.54% of their US portfolio. Moreover, Omni Partners Llp has 4.7% invested in the company for 7.06 million shares. The New York-based Glazer Capital Llc has invested 3.76% in the stock. Harvest Management Llc, a New York-based fund reported 150,000 shares.#img1#

Celator Pharmaceuticals Inc (NASDAQ:CPXX) Ratings Coverage

Ratings analysis reveals 50% of Celator Pharma’s analysts are positive. Out of 6 Wall Street analysts rating Celator Pharma, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $13 while the high is $30.25. The stock’s average target of $21.05 is -30.39% below today’s ($30.24) share price. CPXX was included in 8 notes of analysts from July 27, 2015. Janney Capital initiated Celator Pharmaceuticals Inc (NASDAQ:CPXX) on Tuesday, March 15 with “Buy” rating. Roth Capital maintained Celator Pharmaceuticals Inc (NASDAQ:CPXX) on Tuesday, March 15 with “Buy” rating. On Tuesday, May 31 the stock rating was downgraded by Roth Capital to “Neutral”. TH Capital maintained the stock with “Buy” rating in Monday, July 27 report. The stock of Celator Pharmaceuticals Inc (NASDAQ:CPXX) has “Hold” rating given on Wednesday, June 1 by Needham. Needham initiated Celator Pharmaceuticals Inc (NASDAQ:CPXX) on Tuesday, April 12 with “Buy” rating. Stifel Nicolaus downgraded the shares of CPXX in a report on Wednesday, June 1 to “Hold” rating. The rating was maintained by H.C. Wainwright on Tuesday, March 15 with “Buy”.

More notable recent Celator Pharmaceuticals Inc (NASDAQ:CPXX) news were published by: Fool.com which released: “Why Celator Pharmaceuticals, Inc. Soared Higher Today” on March 21, 2016, also Fool.com with their article: “Is Celator Pharmaceuticals, Inc. a Stock Worth Buying?” published on April 01, 2016, Prnewswire.com published: “Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of …” on June 03, 2016. More interesting news about Celator Pharmaceuticals Inc (NASDAQ:CPXX) were released by: Fool.com and their article: “Why Celator Pharmaceuticals Is Up 1610% in 2016” published on June 27, 2016 as well as Fool.com‘s news article titled: “Why Celator Pharmaceuticals Shares Skyrocketed 100% in May” with publication date: June 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>